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Mouse and Human CRKL Is Dosage Sensitive
for Cardiac Outflow Tract Formation
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Elaine Zackai,2 Beverly S. Emanuel,2 Bin Zhou,1 Birgit Funke,4 and Bernice E. Morrow1,*
The human chromosome 22q11.2 region is susceptible to rearrangements during meiosis leading to velo-cardio-facial/DiGeorge/
22q11.2 deletion syndrome (22q11DS) characterized by conotruncal heart defects (CTDs) and other congenital anomalies. The majority
of individuals have a 3 Mb deletion whose proximal region contains the presumed disease-associated gene TBX1 (T-box 1). Although a
small subset have proximal nested deletions including TBX1, individuals with distal deletions that exclude TBX1 have also been iden-
tified. The deletions are flanked by low-copy repeats (LCR22A, B, C, D). We describe cardiac phenotypes in 25 individuals with atypical
distal nested deletions within the 3 Mb region that do not include TBX1 including 20 with LCR22B to LCR22D deletions and 5 with
nested LCR22C to LCR22D deletions. Together with previous reports, 12 of 37 (32%) with LCR22B–D deletions and 5 of 34 (15%) in-
dividuals with LCR22C–D deletions had CTDs including tetralogy of Fallot. In the absence of TBX1, we hypothesized that CRKL
(Crk-like), mapping to the LCR22C–D region, might contribute to the cardiac phenotype in these individuals. We created an allelic series
in mice of Crkl, including a hypomorphic allele, to test for gene expression effects on phenotype. We found that the spectrum of heart
defects depends on Crkl expression, occurring with analogous malformations to that in human individuals, suggesting that haploinsuf-
ficiency of CRKL could be responsible for the etiology of CTDs in individuals with nested distal deletions andmight act as a geneticmod-
ifier of individuals with the typical 3 Mb deletion.Introduction
Congenital heart disease (CHD) is the most common type
of birth defect in humans. It occurs in nearly 1% of all live
births and is considered the major cause of infant mortal-
ity.1 Many individuals require surgical intervention during
the first year of life for survival. Overall, the quality of life
of individuals with CHD is often compromised. Despite its
clinical relevance, the genetic cause of most CHD remains
unknown. The majority is of sporadic occurrence perhaps
caused by a combination of genetic and environmental
risk factors.2 Studies of rare genetic CHD syndromes might
help pinpoint genes whose contribution to disease risk
and mechanism can be better understood in animal
models.
Velo-cardio-facial syndrome (MIM 192430) or DiGeorge
syndrome (MIM 188400), also known as 22q11.2 deletion
syndrome (22q11DS), is a congenital malformation disor-
der occurring in 1/4,000 live births.3 It is characterized
by extensive phenotypic variability that has been the sub-
ject of intensive research. Approximately 70% of affected
individuals have a conotruncal type of heart defect (CTD;
e.g., tetralogy of Fallot [TOF], interrupted aortic arch type
B [IAAB], persistent truncus arteriosus [PTA]) and/or aortic
arch anomalies (AAAs; e.g., right-sided aortic arch). More
than 90% of individuals have a 3 Mb deletion. The dele-
tion is usually de novo in occurrence and is caused by
meiotic non-allelic homologous recombination events be-
tween flanking low-copy repeats termed LCR22. There are1Department of Genetics, Albert Einstein College of Medicine, Yeshiva Unive
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are LCR22A, LCR22B, LCR22C, and LCR22D (Figure 1).
The typical 3 Mb deletion is flanked by LCR22A and
LCR22D (LCR22A–D). More than 45 known genes map
to the 3 Mb interval and are dispersed throughout the re-
gion. Approximately 10% of individuals have a proximal
nested 1.5 Mb deletion between LCR22A and LCR22B,
and 5% have a 2.0 Mb deletion between LCR22A and
LCR22C.6,7 The 1.5 Mb LCR22A–B region has been consid-
ered the critical region for the syndrome.8,9 TBX1 (T-box 1;
Figure 1) (MIM 602054), mapping to the critical LCR22A–B
interval, is the strongest candidate gene for CTDs as deter-
mined by studies of mouse models.10,11 Furthermore,
mutations in TBX1 were discovered in a handful of non-
deleted human individuals with a subset of clinical fea-
tures of 22q11DS.12,13
Studies of mouse models also implicated another gene,
the cytoplasmic adaptor CRKL (v-crk avian sarcoma virus
CT10 oncogene homolog-like) (MIM 602007), in the etiol-
ogy of 22q11DS.14 However, CRKLmaps to the LCR22C–D
interval and is thus outside the presumed critical
region (Figure 1). Interestingly, over the past few years
individuals with distal LCR22B–D and nested LCR22C–D
deletions that do not include TBX1 have been re-
ported.6,7,15,16 There are 11 coding genes (10 known genes
and 1 predicted gene) in the LCR22C–D region including
PI4KA (phosphatidylinositol 4-kinase, catalytic, alpha
[MIM 600286]), SERPIND1 (serpin peptidase inhibitor,
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Figure 1. The 22q11.2 Region and
LCR22s
Schematic representation of the 22q11.2
region showing the different sizes of dele-
tions. Low-copy repeats on chromosome
22q11.2 (LCR22) are represented by letters
A, B, C, D (sizes not to scale). A subset of
the genes in the 22q11.2 region is shown.SNAP29 (synaptosomal-associated protein, 29 kDa [MIM
604202]), CRKL, LOC1019288, AIFM3 (apoptosis-inducing
factor, mitochondrion-associated, 3), LZTR1 (leucine-
zipper-like transcription regulator 1 [MIM 600574]),
THAP7 (THAP domain containing 7 [MIM 609518]),
P2RX6 (purinergic receptor P2X, ligand-gated ion channel,
6 [MIM 608077]), SLC7A4 (solute carrier family 7, member
4 [MIM 603752]), and LRRC74B (leucine rich repeat con-
taining 74B). Based upon previous mouse genetic studies,
CRKL is the strongest candidate gene for the cardiac
phenotype in the region and thus worthy of further studies
in mouse models.14,17,18
Although Tbx1 has been extensively studied in mouse
models, Crkl has been given less attention with regard to
22q11DS. Crkl belongs to the Crk family of cytoplasmic
protein adaptors that includes itself19 and Crk (v-crk avian
sarcoma virus CT10 oncogene homolog) (CRKI, CRKII,
and CRKIII, three spliced variants [MIM 164762]).20,21
Both Crk and Crkl are evolutionally conserved from nem-
atodes to vertebrates and encode ubiquitously expressed
proteins that play essential roles in signal transduction,
such as MAPK signaling. Of note, CRK maps to human
chromosome 17, not 22q11.2. Both CRK and CRKL
mediate tyrosine kinase signaling to regulate cell prolifera-
tion, differentiation, adhesion, and migration.22 They are
also recognized as key components in cancer metastasis
and invasion.23,24 Despite their similar sequence, they
have independent roles during mammalian development.
There have been a few important mouse studies of Crk and
Crkl during embryogenesis. In particular, loss of function
of either gene results in lethality due to the presence of
embryonic malformations including CHD. Crk-null mice
have vascular smooth muscle cell defects causing dilata-
tion and rupture of blood vessels.25 They also have thin
myocardial walls with normal-appearing conotruncal
and valvular structures.25 Crkl homozygous null mutant
embryos, on the other hand, have CTDs similar to that
seen in 22q11DS-affected individuals.14 Because of the
presence of similar CTD malformations in Tbx1- and
Crkl-null mutant embryos, and because both genes are
hemizygous in most individuals with 22q11DS, heterozy-
gous intercrosses were performed to uncover a possible236 The American Journal of Human Genetics 96, 235–244, February 5, 2015genetic interaction. Analysis of dou-
ble heterozygous embryos revealed
that Crkl genetically interacts with
Tbx1 for cardiovascular develop-
ment.17 Thus, Crkl might act in the
Tbx1 genetic pathway, possiblyserving as a genetic modifier in humans with the 3 Mb
22q11.2 deletion.
Given these observations, we decided to reexamine the
role that CRKL might play in CHD. We evaluated 25 indi-
viduals with a nested atypical LCR22B–D (n ¼ 20) or
LCR22C–D (n ¼ 5) deletion that is hemizygously deleted
for CRKL and have CTDs but do not have a deletion of
TBX1. When taken together with previous reports, there
are now 71 subjects described with LCR22B–C or
LCR22C–D deletions. Further, we were able to recapitulate
the full spectrum of Crkl dosage effects on cardiac outflow
tract (OFT) development by creating and evaluating a Crkl
allelic series in mice. These data implicate CRKL as an
important human disease gene for CTDs.Material and Methods
Human Study Subjects
A total of 1,232 individuals with 22q11DS were evaluated at The
Children’s Hospital of Philadelphia from 1992 to 2014. The indi-
viduals had deletion sizing performed by a variety of molecular
methods that evolved as technology advanced. Clinical samples,
comprising 62% of the cohort, were evaluated by fluorescence
in situ hybridization (FISH) and more recently by array compara-
tive genomic hybridization (aCGH), genome-wide SNP microar-
ray, or MLPA. Research samples were evaluated by FISH, or more
recently by multiplex-ligation-dependent probe amplification
assays (MLPA;MRCHolland; P023 or P250 SALSA). Echocardiogra-
phy reports were reviewed for each subject. All investigations were
conducted under an IRB-approved protocol at The Children’s Hos-
pital of Philadelphia and Albert Einstein College of Medicine (CCI
1999-201). Informed consent was obtained for all participants.
Generation of Crkl Alleles
We created a Crkl-floxed and Crkl-null allele in mice as shown in
Figure S1. To generate a Crkl floxed allele, we first inserted a single
loxP site upstream of the first exon of Crkl (Figure S1; yellow). We
inserted a Neomycin cassette flanked by two loxP sites downstream
of exon 1 (Figure S1; orange and green). There were a total of three
loxP sites in the Crkl locus, and the mice were termed Crkl-NEO/þ.
To generate a null allele, we crossed floxed mice with CMV-Cre
mice and screened resulting animals by PCR. The mouse lines
used have been generated for the purpose of this study and they
are Crkl-NEO/þ and Crklþ/ or Crkl-HET. We backcrossed each line
or intercrossed them in order to obtain all the possible allelic com-
binations: Crklþ/þ or Crkl-WT, Crkl-HET, Crkl-NEO/þ, Crkl-NEO/
NEO, Crkl-NEO/, and Crkl/ or Crkl-KO. All mice have been
maintained congenic in the Swiss Webster background. PCR stra-
tegies for mouse and embryos genotyping are available upon
request.
Quantitative RT-PCR
To obtain enough total RNA and minimize the variability of gene
expression in individual embryos, each RNA sample containedmi-
crodissected hearts from three embryos of the same genotype at
E10.5. Three biological replicates were performed per genotype.
The tissue was isolated and immediately frozen, and samples
were homogenized in Buffer RLT (QIAGEN). Total RNA was iso-
lated with the RNeasy Micro Kit (QIAGEN) according to the man-
ufacturer’s protocol. Quality and quantity of total RNA was
determined with an Agilent 2100 Bioanalyzer (Agilent) and a
ND-1000 Spectrophotometer (NanoDrop), respectively. Single-
stranded cDNA targets were amplified from 100 ng starting total
RNA with the Ovation RNA Amplification System V2 and FL-
Ovation cDNA Biotin Module V2 (NuGEN). The mRNA levels
were measured by TaqMan Gene Expression Assays (Applied Bio-
systems) for each gene and were carried out in triplicate with
18S (RNA, 18S ribosomal 1), Actb (Actin, beta), and B2m (Beta-2-
microglobulin) genes as normalization controls. TaqMan probes
and primer sets were obtained from the Applied Biosystems
Gene Expression Assay database. Samples were run in standard
96-well plates (20 ml final volume per reaction and each reaction
in triplicate) on an ABI 7900HT Q-PCR apparatus. The SDS 2.2
software platform (Applied Biosystems) was used for the computer
interface with the ABI 7900HT PCR System to generate normalized
data, compare samples, and calculate the relative quantity. Statis-
tical significance of the difference in gene expression was esti-
mated by the two-tailed t test.
Mouse Heart Histology and Phenotypic Analysis
Mouse embryos were isolated in PBS and fixed in 10%neutral buff-
ered formalin (Sigma) overnight. After fixation, the embryos were
dehydrated through a graded ethanol series, embedded in paraffin,
and sectioned at 5 mm. All histological sections were stained with
hematoxylin and eosin by standard protocols. Staining was per-
formed in the Einstein Histopathology Core Facility. A total of
118 hearts at E15.5 were obtained from approximately 50
independent crosses and analyzed morphologically via light
microscopy.
Phenotype-Genotype Heatmap
For both human and mouse samples, we created a phenotype ma-
trix indicating the cardiac phenotypes found in each sample. We
used the heatmap R package to create the phenotype-genotype
correlation shown as heatmaps. Clustering distances for x and y
axes were calculated by Euclidean distance measures.Results
Congenital Heart Defects in Individuals with the
Nested LCR22B–D Deletion
The LCR22B–D region is 0.75 Mb in size, excluding the
flanking LCR22s (chr22: 20,726,074–21,472,008; hg19)The Americor 1.6 Mb including the LCR22s (chr22: 20,274,541–
21,921,290). We evaluated 20 newly ascertained, unrelated
persons with the 22q11.2, LCR22B–D deletion (Figure 1)
with known heart phenotype information based upon
echocardiography reports (Table S1). Overall, 8 of the 20
individuals (40%) had cardiac malformations of which
half were conotruncal type defects (CTDs). We observed
tetralogy of Fallot (TOF; n ¼ 2), persistent truncus arterio-
sus (PTA; n ¼ 1), interrupted aortic arch type B (IAA type B;
n ¼ 1), isolated subaortic ventricular septal defects (VSDs;
n ¼ 4), and atrial septal defects (ASDs; n ¼ 2). Two individ-
uals had more than one cardiac anomaly, such as VSD and
ASD. We then combined our results with 17 previously
published cases, of which 10 were unrelated probands
and 7 were family members.6,7,15,26 Taken together, 12/
37 (32%) individuals with LCR22B–D deletions had CHD
(Figure 2A). To better visualize the comparison, we created
a heatmap in which we focused on phenotypes with
respect to the position of the deletion on chromosome
22q11.2 (Figure 2B). Among the 12 individuals with
LCR22B–D deletions that had CHD, the most common de-
fects were TOF (3/12; 25%) and isolated subaortic VSDs
(4/12; 33%). Other less common defects in previously re-
ported persons with LCR22B–D deletions included aortic
arch anomalies, PTA, and double outlet right ventricle
(DORV) (Figure 2B).
Cardiac Defects in Individuals with the LCR22C–D
Deletion
The LCR22C–D deletion spans 0.4 Mb, excluding the
LCR22 sequences (chr22: 21,062,071–21,466,724). Of the
five persons ascertained (Table S1) with the LCR22C–D
deletion (Figure 1), one of them had TOF and the rest did
not have a heart defect. From the literature of 19 unrelated
probands and 10 family members, 2 had TOF and 2 had
both a VSD and ASD.15–20,26 Thus a total of 5/34 (15%)
of individuals with an LCR22C–D deletion had CHD
(Figure 2A), including TOF in 3/5 (60%; Figure 2B).
Eight LCR22s span the 22q11.2 region: LCR22A, B, C, D,
E, F, G, and H. There are six published cases of atypical de-
letions flanking LCR22C that extend beyond LCR22D
(termed LCR22C–D-plus in this study; reviewed by Rump
et al.)26 These deletions include CRKL as well as MAPK1
(mitogen-activated protein kinase 1) (MIM 176948), a
CRKL pathway gene (Figure 1). A total of 5/6 (83%) of these
individuals had CHD, including a VSD and ASD (Figure 2).
Of interest, OA and VSD, comprising two components of
TOF (Figure S3), was observed in one previously reported
individual with an atypical LCR22C–D-plus deletion that
extended beyond LCR22D26 (Figure 2B). Overall, these
distal deletions with CRKL further suggest its contribution
to CHD in these individuals.
Generation of an Allelic Series with Varying Crkl
mRNA Dosage
One important question has been whether the function of
CRKL is sensitive to altered gene dosage in humans.an Journal of Human Genetics 96, 235–244, February 5, 2015 237
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Figure 2. Congenital Heart Defects in Human and Mouse
(A) Percentages of CHD in all available human and mouse genotypes relevant for this study. Genotypes consisted of wild-type, Crkl-WT,
hypomorphic (Crkl-NEO/NEO and Crkl-NEO/), and null (Crkl-KO).
(B and C) Human LCR22B–D deletion is indicated as B-D; LCR22C–D deletion is indicated as C-D, LCR22C to beyond LCR22D is indi-
cated as C-D-plus. Genotype-phenotype heatmaps indicating phenotype status for each subject with CHD are given for human (B) and
mouse (C) data.
(B) Human subjects with LCR22B–D or LCR22C–D deletions are shown along the x axis. The various reported cardiac phenotypes are
shown on the y axis. The most common phenotype is TOF, which includes an OA with VSD, associated with a hypertrophic right
ventricle (thick ventricle; TV) and PS. ABAAM (abnormal branch arch artery morphology) and DORV are seen only in subjects with
LCR22B–D deletions.
(C) Mouse samples with different Crkl alleles are shown along the x axis and observed phenotypes are shown along the y axis. Mice with
the lowest level of Crkl expression have DORV or TOF. In mouse embryo tissue sections, TOF is defined as the presence of OA, VSD, TV,
and PS. Row and column clusteringwas performed by Euclidean distancemeasures. Abbreviations are as follows: ASD, atrial septal defect;
ABAAM, abnormal branchial (pharyngeal) arch artery morphology; DORV, double outlet right ventricle; PTA, persistent truncus arterio-
sus; VDS, ventricular septal defect; TV, thick ventricular wall; OA, overriding aorta; and PS, pulmonary stenosis. ‘‘Other’’ represents non-
conotruncal cardiac defects.Although Crkl-HET mice have no heart defects, Crkl-KO
embryos have previously been reported to have VSDs, oc-
casionally with cardiac outflow tract alignment defects
such as DORVor an overriding aorta (OA).14,18 In histolog-
ical sections from late-gestational-stage mouse embryos,
TOF is defined as OA, VSD, hypertrophic right ventricle
(RV), and pulmonic stenosis (PS). TOF is similarly defined
in humans by echocardiography, and in particular requires
anterior malalignment of the conal septum with mitral to
aortic valve fibrous continuity. An OA and PS are also char-
acteristic, as is hypertrophic RV, occurring as a secondary
defect. These working definitions allow for the comparison
between the different kinds of data generated from human
individuals and mouse embryos.
To try to generate the full spectrum of phenotypes
observed in human subjects in a mouse model, we took
advantage of the fact that insertion of a Neomycin cassette238 The American Journal of Human Genetics 96, 235–244, Februaryinto introns occasionally interferes with expression of that
gene and can produce hypomorphic models.27 We
generated a hypomorphic mouse line, Crkl-NEO/NEO
(Figure S1), that expresses Crkl mRNA at a lower level
than the Crkl-HET mouse line (Figure 3A). To examine
the phenotype in the hypomorphic mice, we intercrossed
Crkl-NEO/þmice and found that most Crkl-NEO/NEOmice
died before birth (expected frequency, 1:4; observed fre-
quency, 1:30; i.e., three pups with this genotype were
found out of 100 pups recovered from at least 10 indepen-
dent mating pairs). To test whether the Neomycin cassette
reduced expression of Crkl mRNA, two Crkl mouse lines,
Crkl-HET and Crkl-NEO/þ, were crossed to obtain six
different allelic combinations. Quantitative RT-PCR was
performed as shown in Figure 3B. The presence of
the Neomycin cassette reduced expression of Crkl as com-
pared to the normal level (Figure 3B). The heterozygous5, 2015
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Figure 3. Generation of an Allelic Series
with Varying Crkl mRNA Expression
(A) Schematic of the Crklmouse alleles and
cardiac expression. Exons are indicated by
large black boxes. An allelic series of Crkl
expression was obtained by specific ge-
netic crosses that allowed all possible com-
bination of two of the three alleles
described, i.e., a, b, and c. The normal
locus (a), the floxed allele (loxP, triangle)
containing the Neomycin cassette (NEO)
(b), and the recombined allele (c) are
shown.
(B and C) The fold change (FC) from quan-
titative RT-PCR (qRT-PCR) assays to detect
Crkl mRNA dosage in mouse hearts at
E10.5 isolated from each genotype is indi-
cated. All mice were maintained in a pure
Swiss-Webster genetic background. The
fold change (FC 5 SD) of Crkl mRNA
expression in the allelic series with respect
to the wild-type were as follows: Crkl-WT
(1 5 0.049), Crkl-HET (0.465 5 0.02),
and Crkl-KO (0.003 5 0.0001) hearts
and Crkl-WT (1 5 0.049), Crkl-NEO/þ
(0.436 5 0.059), Crkl-NEO/NEO (0.025 5
0.006), and Crkl-NEO/ (0.013 5 0.003)
alleles are shown. Statistical significance
of the difference in gene expression
was estimated by the two-tailed t test,
p values% 0.01. All cross comparisons be-
tween the above-mentioned genotypes
were significantly different except for
NEO/þ versus HET and NEO/NEO versus
NEO/.Crkl-NEO/þ allele had expression levels similar to Crkl-HET
values. Embryonic hearts from the Crkl-NEO/NEO geno-
type had a greatly reduced level of Crkl expression
(Figure 3B). Expression levels in Crkl-NEO/NEO and Crkl-
NEO/ hearts were not significantly different. Overall,
this tells us that the Crkl-NEO allele behaves as a hypomor-
phic allele.
One concern with the Neomycin cassette is that it might
modify expression of neighboring genes. This would result
in a phenotype unrelated to that of our gene of interest. To
test this, we measured the expression levels of eight genes
in the LCR22C–D region (Figure 4) by qRT-PCR. We found
that theNeomycin cassette did not alter the expression level
of any of them (Figure 4), confirming that the Neomycin
cassette in this mouse model affected only Crkl expression.
Of interest, one of the selected genes, Aifm3, was increased
in expression when the dosage of Crkl was decreased. This
is unrelated to the presence of the Neomycin cassette,
because expression of Aifm3 in Crkl-NEO/NEO and Crkl-
KO embryos did not differ (Figure 4).The American Journal of Human GeSeverity of OFT Defects Is Sensitive
to Crkl Expression Levels in the
Mouse
The Crkl allelic series, in order of
decreasing expression, consists of
Crkl-WT, Crkl-HET, Crkl-NEO/þ, Crkl-
NEO/NEO, Crkl-NEO/, and Crkl-KO genotypes. To delin-
eate the spectrum of heart defects in embryos of the Crkl
allelic series, we examined the hearts from 118 embryos
at E15.5 (percentages of CHD are shown in Figure 2A; de-
tails in Table S2). To better visualize the comparison, we
created a heatmap in which we focused on phenotypes
with respect to Crkl dosage (Figure 2C). We selected the
time point of E15.5 because that is 1 day in embryonic
development prior to the death of Crkl-KO embryos.14
The distribution of percentage of different OFT cardiac
phenotypes within the groups of similar genotypes is
shown in Figure 5. CHD phenotypes were present in 21/
25 (84% overall; 32% CTD only) of Crkl-NEO/NEO em-
bryos, 13/15 (87% overall, of which all were CTDs) of
Crkl-NEO/ embryos, and 24/24 (100% over all; 46%
CTD only) of Crkl-KO embryos. Non-CTD phenotypes
included myocardial and valvular defects. The hypomor-
phic embryos, Crkl-NEO/NEO and Crkl-NEO/, displayed
similar CHD patterns to those found in humans with the
distal nested deletions.netics 96, 235–244, February 5, 2015 239
Figure 4. Gene Expression of Crkl Neigh-
boring Genes
Quantitative RT-PCR of genes in the
LCR22B–D region flanking Crkl. Similar
qRT-PCR assays were performed as in Fig-
ures 3B and 3C. Mouse hearts were isolated
from Crkl-WT, Crkl-NEO/þ, Crkl-NEO/NEO,
and Crkl-KO hearts at E10.5. Expression
values are shown as fold change and error
bars are the standard deviations (FC 5
SD). Statistical significance of the differ-
ence in gene expression was estimated by
the two-tailed t test, p values% 0.01.The most common CHD in humans with the LCR22B–D
or nested deletions is an isolated subaortic VSD (Figure 2A).
Inmice, isolated VSDswith normally aligned outflow tracts
or associatedwith amild alignment defect as OA (Figure S2)
occurred with increasing frequency as Crkl expression level
increased. In contrast, TOF and DORV, which are severe
alignment defects, occurred with increasing frequency as
Crkl expression decreased (Figure 5B). Specifically, TOF
occurred in 1/25 of Crkl-NEO/NEO embryos (4%), 3/15 in
Crkl-NEO/ embryos (20%), and 6/24 of Crkl-KO embryos
(25%) (Figure 5B). Similarly, DORV occurred in 2/25 Crkl-
NEO/NEO (8%), 10/15 Crkl-NEO/ (67%), and 5/24 Crkl-
KO (21%) embryos. In contrast, OA with no other outflow
tract defect occurred in 5/25 Crkl-NEO/NEO embryos
(20%) but did not occur in Crkl-NEO/ and Crkl-KO em-
bryos. These data suggest that the severity of the cardiac
defects in Crkl mutant embryos is sensitive to altered
expression. It also indicates thatCrklhypormorph embryos
have a similar penetrance and expressivity to that found in
human individuals with distal deletions. When taken
together, it supports the idea that CRKL is dosage sensitive
for function in humans.Discussion
In this report, we describe individualswith variant chromo-
some 22q11.2 deletions in the distal half of the 3Mb region
that exclude TBX1, with clinical features of 22q11DS (velo-
cardio-facial/DiGeorge syndrome). We refer to these as
nested LCR22B–D and LCR22C–D distal deletions. CRKL,
mapping to the LCR22C–D region, among other genes is
hemizygously deleted. By generating an allelic series, we
demonstrated that Crkl is sensitive to reduced gene expres-
sion for cardiac OFT development. Overall, our data impli-
cate CRKL as a disease-associated gene for individuals with
nested distal 22q11.2 deletions andwe suggest that it could240 The American Journal of Human Genetics 96, 235–244, February 5, 2015act as a modifier of CTDs for those
with the typical hemizygous 3 Mb
22q11.2 deletion.
The Mouse Crkl Allelic Series
Among the different alleles we ob-
tained, the hypomorphic Crkl-NEO/NEO and Crkl-NEO/ alleles elicit the full range of different
CTDs that occur in individuals with nested distal deletions.
Neither the Crkl-HET nor the Crkl-KO embryos are optimal
models because they have either no phenotype or addi-
tional intracardiac muscle or valve defects, respectively.
The cardiac OFT defects between the Crkl-NEO/NEO and
Crkl-NEO/ embryos were compared. Of interest, the pene-
trance and expressivity of particular CTDs were quite
different, despite the fact that the expression levels of
Crkl in these two allelic combinations were not considered
different based on a statistical evaluation. The mice were
maintained in the same congenic background, implicating
subtle changes in Crkl expression as being responsible for
the differences in the phenotype in mutant embryos.
This suggests that there is a specific threshold of Crkl
expression that when reduced beyond a particular level
greatly affects heart development. For example, it is likely
that there is a gradient effect for Crkl expression. It might
be possible to observe such changes at the protein level
or with respect to changes in phosphorylation of down-
stream effector proteins. Either way, we consider the Crkl
hypomorph to be a unique tool to study causes of genetic
variability of heart development.
Based upon the frequency of specific malformations pre-
sent, the hypomorphic alleles might make it possible to
understand the molecular etiology of individual cardiac
OFT phenotypes. In addition, the Crkl hypomorph mouse
models might help to identify genes that act in the same
genetic pathway as Crkl. The usual genetic strategy to iden-
tify genes that can regulate Crkl expression or act down-
stream of MAPK signaling involves intercrosses between
two different heterozygous mouse alleles. Frequently, dou-
ble heterozygous mice have a mild phenotype or one with
reduced penetrance. The Crkl-NEO/NEO or Crkl-NEO/
mouse model might provide an advantage in such genetic
interaction studies because the threshold needed to
observe a phenotype is reduced. It also suggests that
AB
Figure 5. Conotruncal Defects and Crkl
Alleles
(A) Categories of cardiac outflow tract defects
in Crkl mutant mouse embryos. Percent of
embryos with cardiac defects in the three ge-
notypes of Crkl that disrupts cardiac outflow
tract development (Crkl-NEO/NEO ¼ 25,
Crkl-NEO/ ¼ 15, Crkl-KO ¼ 24). Note that
one embryo can have multiple defects (Table
S2). Distribution of outflow tract defects
TOF, DORV, and OA.
(B) TOF in a Crkl-KO embryo. Transverse his-
tological sections of a Crkl-WT (a, b) and
Crkl-KO (c, d) embryonic mouse heart at
E15.5 stained with hematoxylin and eosin.
Arrow (c) shows misalignment of the Ao
and PV. Star (c) shows PS. Arrowhead (d)
shows a VSD. Abbreviations are as follows:
RA, right atrium; RV, right ventricle; LA, left
atrium; LV, left ventricle; Ao, Aorta; PV, pul-
monary valve; VS, ventricular septum.genetic variations in human CRKL might act as a genetic
modifier of CTDs in individuals with the 3 Mb deletion.
Cardiac Genotype to Phenotype Correlations in
Individuals with LCR22B–D versus LCR22C–D
Deletions
We describe individuals with nested LCR22B–D deletions
harboring CTDs as well as those reported in the literature.
Such nested deletions are only now being recognized in
the clinical lab given the advent of genome-wide molecu-
lar testing. One important goal is to determine which
gene(s) are responsible for the etiology of the human
nested distal deletion phenotype. There are 11 coding
genes (10 known and 1 predicted) in the LCR22C–D re-
gion: PI4KA, SERPIND1, SNAP29, CRKL, LOC1019288,
AIFM3, LZTR1, THAP7, P2RX6, SLC7A4, and LRRC74B
(Table S3). One question is whether haploinsufficiency of
any of the other genes could contribute to the phenotype
in affected individuals. One gene of interest is SNAP29The American Journal of Humanbecause it is already known to be associ-
ated with a human disease. SNAP29
encodes a synaptic vesicle protein
that when mutated causes autosomal-
recessive CEDNIK syndrome (cerebral
dysgenesis, neuropathy, ichthyosis,
keratoderma [MIM 609528]). However,
individuals with this disorder do not
have CHD. Another gene in the region
is SERPIND1, which encodes heparin
cofactor II that is important in the
blood coagulation cascade28,29 but is
not required for heart development.
P2RX630,31 and SLC7A432 function in
ion channels and are unlikely to
contribute to cardiac outflow tract
morphogenesis. This leaves six genes
remaining, including CRKL. The fiveother genes are PI4KA, encoding a phosphatidylinositol
kinase,33,34 AIFM3, encoding a mitochondrial protein
that function in inducing apoptosis,35 LZTR1, encoding a
golgi apparatus protein,36 THAP7, encoding a chromatin
modifier,37,38 and LRRC74B, encoding a protein of un-
known function. Among the LCR22C–D genes besides
CRKL, THAP7 seems interesting because of its function as
a chromatin modifier needed to repress transcription.38,39
However, it does not appear strongly expressed in the
pharyngeal apparatus, which provided progenitor cells to
the OFT or heart.40
One interesting gene is AIFM3 becausemRNA expression
in embryonic hearts was increased in expression when Crkl
was inactivated. AIFM3 is related to AIFM1 (apoptosis-
inducing factor, mitochrondrian-associated-1 [MIM
300169]) and encodes a ubiquitously expressed mitochon-
drial protein that induces apoptosis when overexpressed.41
Overexpression of AIFM3might increase apoptosis, but the
possible function of AIFM3 in heart development is notGenetics 96, 235–244, February 5, 2015 241
known. Because individuals with LCR22B or LCR22C–D
deletions will be hemizygously deleted for AIFM3, the
overall expression level might be normalized. Among all
the other genes in the region, CRKL is the strongest candi-
date gene.
Our work suggests that there might be additional genes
in the LCR22B–C region that contribute to CHD, because
the penetrance is higher in subjects with LCR22B–D than
LCR22C–D deletions. The LCR22B–C interval contains
four coding genes: ZNF74 (zinc finger protein 74 [MIM
194548]), encoding a protein that might be involved in
RNA maturation or transcription,39,42 SCARF2 (scavenger
receptor class F, member 2 [MIM 613619]), in which reces-
sive mutations cause Van Den Ende Gupta syndrome
(MIM 600920) that is not characterized by CHD,43,44
KLHL22 (kelch-like family member 22), which encodes a
protein involved in regulation of chromosome alignment
during meiosis,45,46 and MED15 (mediator complex sub-
unit 15 [MIM 607372]), which encodes a protein that is
part of the Mediator complex needed for RNA polymerase
II transcription.3,7 Among the four genes, MED15 is the
most interesting because it might affect transcription.
Further genetic studies of Med15 are warranted.
HIC2 (hypermethylated in cancer, 2 [MIM 607712]) is
particularly important to discuss with respect to distal
22q11.2 deletions. HIC2 maps to a 15 kb region of unique
sequences that disrupts an internal part of LCR22D, near
its 30 end. The exact function of HIC2 is not known, but
it is related to HIC1, which encodes a tumor suppressor.
A recent study of Hic2 in mouse models demonstrated
that it is sensitive to gene dosage for heart develop-
ment.47 Although Hic2/ embryos die by E10.5, some
Hic2þ/mice show perinatal lethality.47 Of interest, a third
of Hic2þ/ embryos had a VSD with an overriding aorta.47
It is not known definitively whether HIC2 is hemizygously
deleted in individuals that have chromosome endpoints
within LCR22D (LCR22A–D, B–C, or C–D). Definitive
proof would need to come from direct quantitative
sequence analyses. Nonetheless, HIC2 is hemizygously
deleted in individuals with deletions that include a dele-
tion of LCR22D.47 Thus, haploinsufficiency of HIC2might
be an important contributor to that of individuals with
distal chromosome 22q11.2 rearrangements.
Conclusions
In conclusion, our data strongly suggest that haploinsuffi-
ciency of CRKL can contribute to the etiology of CHD in
individuals with nested distal deletions. The allelic series
of altered Crkl expression in mice confirms the possibility
that CRKL is dosage sensitive in humans. This work also
suggests that CRKLmight serve as a genetic modifier of car-
diac anomalies in individuals with the typical 3 Mb,
LCR22A–D deletion. Finally, haploinsufficiency of both
CRKL and MAPK1 might result in a higher frequency of
CHD. This would suggest that the CRKL-MAPK pathway
might be important in human cardiac development and
disease.242 The American Journal of Human Genetics 96, 235–244, FebruarySupplemental Data
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